Contact
searchSearch
HMP Global
Login

GPRC5D

Videos

Sundar Jagannath, MD, Mount Sinai
Videos
Bispecific Antibodies, CAR T-Cell Therapy, and BCMA-Directed Therapy for the Treatment of Multiple Myeloma With Curative Intent
02/23/2023
Sundar Jagannath, MD, provides an update on how immunotherapy and cellular therapy are changing treatment approaches for multiple myeloma.
Sundar Jagannath, MD, provides an update on how immunotherapy and cellular therapy are changing treatment approaches for multiple myeloma.
Sundar Jagannath, MD, provides...
02/23/2023
Oncology
Dan Vogl, MD, University of Pennsylvania
Videos
Bispecific T-Cell Engagers and Novel Approaches for the Treatment of Multiple Myeloma
02/23/2023
Dan Vogl, MD discusses options for bispecific T-Cell engagers when treating patients with multiple myeloma.
Dan Vogl, MD discusses options for bispecific T-Cell engagers when treating patients with multiple myeloma.
Dan Vogl, MD discusses options...
02/23/2023
Oncology
Faith Davies, MD
Videos
What Is the Optimal Combination for Patients With Multiple Myeloma in Early Relapse?
02/16/2023
Faith E. Davies, MD, provides an update on treatment options for patients with multiple myeloma in early relapse at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Faith E. Davies, MD, provides an update on treatment options for patients with multiple myeloma in early relapse at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.
Faith E. Davies, MD, provides an...
02/16/2023
Oncology
Marlana Orloff, MD
Videos
Darovasertib Plus Crizotinib Combination Demonstrates Meaningful Clinical Benefit in Metastatic Uveal Melanoma
06/15/2026
Marlana Orloff, MD, discusses results from the phase 2 OPTIMUS-2 trial showing that darovasertib plus crizotinib significantly improved progression-free survival, response rates, and disease control compared with investigator’s choice therapy...
Marlana Orloff, MD, discusses results from the phase 2 OPTIMUS-2 trial showing that darovasertib plus crizotinib significantly improved progression-free survival, response rates, and disease control compared with investigator’s choice therapy...
Marlana Orloff, MD, discusses...
06/15/2026
Oncology
Omar Nadeem, MD
Videos
Teclistamab Achieves Deep MRD-Negative Responses in High-Risk Smoldering Myeloma
06/15/2026
Omar Nadeem, MD, discusses results from the phase 2 ImmunoPRISM trial evaluating teclistamab in patients with high-risk smoldering multiple myeloma.
Omar Nadeem, MD, discusses results from the phase 2 ImmunoPRISM trial evaluating teclistamab in patients with high-risk smoldering multiple myeloma.
Omar Nadeem, MD, discusses...
06/15/2026
Oncology
Vincent Chung, MD
Videos
Pembrolizumab and Olaparib Combination Demonstrates Signals of Activity in BRCA-Mutated Pancreatic Cancer
06/12/2026
Vincent Chung, MD, disucsses results from the phase 2 SWOG S2001 trial which demonstrated that olaparib plus pembrolizumab improved response and progression-free survival in germline BRCA1/2-mutated pancreatic cancer.
Vincent Chung, MD, disucsses results from the phase 2 SWOG S2001 trial which demonstrated that olaparib plus pembrolizumab improved response and progression-free survival in germline BRCA1/2-mutated pancreatic cancer.
Vincent Chung, MD, disucsses...
06/12/2026
Oncology
Alicia Morgans, MD
Videos
Enzalutamide Associated with Increased Cognitive Decline in in Advanced Prostate Cancer
06/12/2026
Alicia Morgans, MD, discusses results from the ARACOG trial which demonstrated that greater enzalutamide was associated with greater cognitive decline compared with darolutamide in patients with advanced prostate cancer.
Alicia Morgans, MD, discusses results from the ARACOG trial which demonstrated that greater enzalutamide was associated with greater cognitive decline compared with darolutamide in patients with advanced prostate cancer.
Alicia Morgans, MD, discusses...
06/12/2026
Oncology
Janice Mehnert, MD
Videos
Adjuvant Pembrolizumab Reduces Distant Recurrence Risk in Merkel Cell Carcinoma
06/12/2026
Janice Mehnert, MD
Janice Mehnert, MD, discusses updated phase 3 STAMP trial results showing that adjuvant pembrolizumab improved distant metastasis-free survival in patients with surgically treated Merkel cell carcinoma, while exploratory analyses suggested...
Janice Mehnert, MD, discusses updated phase 3 STAMP trial results showing that adjuvant pembrolizumab improved distant metastasis-free survival in patients with surgically treated Merkel cell carcinoma, while exploratory analyses suggested...
Janice Mehnert, MD, discusses...
06/12/2026
Oncology
Oleg Gluz, MD
Videos
Longer Docetaxel-Based Chemotherapy Associated With Improved Outcomes in High-Risk HR-Positive, HER2-Negative Breast Cancer
06/11/2026
Oleg Gluz, MD
Oleg Gluz, MD, discusses pooled analyses from the PlanB and ADAPT trials suggesting that longer docetaxel-based chemotherapy may improve outcomes in patients with high-risk HR-positive, HER2-negative early breast cancer.
Oleg Gluz, MD, discusses pooled analyses from the PlanB and ADAPT trials suggesting that longer docetaxel-based chemotherapy may improve outcomes in patients with high-risk HR-positive, HER2-negative early breast cancer.
Oleg Gluz, MD, discusses pooled...
06/11/2026
Oncology
Thumbnail
Videos
How to Implement Subcutaneous Immuno-Oncology for Providers
06/11/2026
Roxana Dronca, MD; Samantha Guild, JD; Jennifer Hunze, MSN, RN; Lucia Nolan, PharmD
Experts discuss practical considerations for implementing subcutaneous immunotherapy in melanoma care, including workflow integration, operational planning, and patient access.
Experts discuss practical considerations for implementing subcutaneous immunotherapy in melanoma care, including workflow integration, operational planning, and patient access.
Experts discuss practical...
06/11/2026
Oncology
Thumbnail
Videos
Advantages of Subcutaneous Immuno-Oncology for Patients
06/11/2026
Roxana Dronca, MD; Samantha Guild, JD; Jennifer Hunze, MSN, RN; Lucia Nolan, PharmD
Experts discuss the patient-centered advantages of subcutaneous immunotherapy for melanoma, including reduced treatment time and greater flexibility in care delivery.
Experts discuss the patient-centered advantages of subcutaneous immunotherapy for melanoma, including reduced treatment time and greater flexibility in care delivery.
Experts discuss the...
06/11/2026
Oncology
Thumbnail
Videos
Subcutaneous Immuno-Oncology Options Available for Metastatic Melanoma
06/11/2026
Roxana Dronca, MD; Samantha Guild, JD; Jennifer Hunze, MSN, RN; Lucia Nolan, PharmD
Experts review the evidence supporting subcutaneous immunotherapy options for melanoma and discuss how pharmacokinetic, efficacy, and safety data inform their use in clinical practice.
Experts review the evidence supporting subcutaneous immunotherapy options for melanoma and discuss how pharmacokinetic, efficacy, and safety data inform their use in clinical practice.
Experts review the evidence...
06/11/2026
Oncology
Thumbnail
Videos
Standard Immuno-Oncology Options for the Melanoma Landscape and Unmet Needs for Patients
06/11/2026
Roxana Dronca, MD; Samantha Guild, JD; Jennifer Hunze, MSN, RN; Lucia Nolan, PharmD
Experts review the evolving immuno-oncology landscape in melanoma and discuss considerations that influence treatment selection beyond efficacy alone.
Experts review the evolving immuno-oncology landscape in melanoma and discuss considerations that influence treatment selection beyond efficacy alone.
Experts review the evolving...
06/11/2026
Oncology
OLN

GPRC5D

ALIASES

G-protein coupled receptor family C group 5 member D

References

G protein-coupled receptor class C group 5 member D (GPRC5D) is a gene expressed in the hair follicle and malignant bone marrow plasma cells.1 G protein-coupled receptor proteins are cell surface receptors located in the plasma membrane. Activation of the protein occurs when it binds to an external signaling molecule, which causes a conformational change and triggers an interaction between the protein and an available G protein.2

Understanding the Role of GPRC5D

Expression Percentages per Cancer Type

Multiple Myeloma
88%

Resources

News
GPRC5D-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
03/23/2023
Amber Denham
Phase 1 results from the POLARIS trial demonstrate that GPRC5D-targeted CAR-T cell therapy (OriCAR-017) is a promising treatment modality for patients with relapsed/refractory multiple myeloma.
Phase 1 results from the POLARIS trial demonstrate that GPRC5D-targeted CAR-T cell therapy (OriCAR-017) is a promising treatment modality for patients with relapsed/refractory multiple myeloma.
Phase 1 results from the POLARIS...
03/23/2023
Oncology
News
Promising Clinical Efficacy for GPRC5D-Targeting CAR-T Cell Therapy in R/R Multiple Myeloma
03/23/2023
Amber Denham
GPRC5D-targeting CAR-T cell therapy demonstrated a promising clinical efficacy and manageable safety profile in patients with relapsed/refractory multiple myeloma.
GPRC5D-targeting CAR-T cell therapy demonstrated a promising clinical efficacy and manageable safety profile in patients with relapsed/refractory multiple myeloma.
GPRC5D-targeting CAR-T cell...
03/23/2023
Oncology
News
Talquetamab Shows Promise as Novel Agent for Patients With Multiple Myeloma
06/20/2022
Yvette C. Terrie, BS Pharm, RPh
Study findings show the novel GPRC5D-targeting T-cell redirecting bispecific antibody, talquetamab, demonstrates substantial activity against MM cell lines and primary MM cells.
Study findings show the novel GPRC5D-targeting T-cell redirecting bispecific antibody, talquetamab, demonstrates substantial activity against MM cell lines and primary MM cells.
Study findings show the novel...
06/20/2022
Oncology
News
Blinatumomab Improves Survival and Reduces Toxicity in Pediatric Patients With High-Risk B-Acute Lymphoblastic Leukemia
06/15/2026
Stephanie Holland
Results from a phase 2 study demonstrated that replacing 2 intensive chemotherapy courses with blinatumomab improved outcomes and reduced treatment-related toxicity in newly diagnosed pediatric patients with high-risk B-cell acute...
Results from a phase 2 study demonstrated that replacing 2 intensive chemotherapy courses with blinatumomab improved outcomes and reduced treatment-related toxicity in newly diagnosed pediatric patients with high-risk B-cell acute...
Results from a phase 2 study...
06/15/2026
Oncology
News
Total Marrow and Lymphoid Irradiation Shows Promise Prior to alloHCT in Relapsed or Refractory Acute Leukemia
06/15/2026
Emily Estrada
Total marrow and lymphoid irradiation combined with high-dose etoposide and cyclophosphamide was feasible and associated with encouraging outcomes in patients with relapsed or refractory acute leukemia undergoing alloHCT, as demonstrated by...
Total marrow and lymphoid irradiation combined with high-dose etoposide and cyclophosphamide was feasible and associated with encouraging outcomes in patients with relapsed or refractory acute leukemia undergoing alloHCT, as demonstrated by...
Total marrow and lymphoid...
06/15/2026
Oncology
FDA Approval
FDA Approves Capivasertib Plus Abiraterone for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
06/12/2026
Stephanie Holland
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase 3 CAPItello-281 trial, the FDA has approved capivasertib plus abiraterone and prednisone for adult patients with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer that is...
Based on results from the phase...
06/12/2026
Oncology
FDA Approval
FDA Approves Belzutifan Plus Pembrolizumab for Patients With Clear Cell Renal Cell Carcinoma
06/12/2026
Stephanie Holland
Based on results from the phase 3 LITESPARK-022 trial, the FDA has approved adjuvant belzutifan plus pembrolizumab for adult patients with clear cell renal cell carcinoma at intermediate- or high risk of recurrence.
Based on results from the phase 3 LITESPARK-022 trial, the FDA has approved adjuvant belzutifan plus pembrolizumab for adult patients with clear cell renal cell carcinoma at intermediate- or high risk of recurrence.
Based on results from the phase...
06/12/2026
Oncology
News
BAFF-R CAR T Therapy May Overcome Antigen Escape in Relapsed B-Cell Lymphoma
06/11/2026
Stephanie Holland
Results from a phase 1 study demonstrated that PMB-CT01 shows encouraging activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study demonstrated that PMB-CT01 shows encouraging activity in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Results from a phase 1 study...
06/11/2026
Oncology
FDA Approval
FDA Approves an Orally Disintegrating Nilotinib Formulation for Patients With Ph-Positive Chronic Myeloid Leukemia
06/11/2026
Stephanie Holland
The FDA has approved an orally disintegrating nilotinib formulation for adults with Ph–positive chronic myeloid leukemia that can be administered with acid-reducing agents and without food restrictions.
The FDA has approved an orally disintegrating nilotinib formulation for adults with Ph–positive chronic myeloid leukemia that can be administered with acid-reducing agents and without food restrictions.
The FDA has approved an orally...
06/11/2026
Oncology
News
KEYNOTE-D46/EVOKE-03 Discontinued After Missing Progression-Free Survival End Point
06/11/2026
Stephanie Holland
Merck and Gilead have discontinued the phase 3 KEYNOTE-D46/EVOKE-03 trial after sacituzumab govitecan plus pembrolizumab failed to achieve a statistically significant PFS benefit in previously untreated metastatic NSCLC.
Merck and Gilead have discontinued the phase 3 KEYNOTE-D46/EVOKE-03 trial after sacituzumab govitecan plus pembrolizumab failed to achieve a statistically significant PFS benefit in previously untreated metastatic NSCLC.
Merck and Gilead have...
06/11/2026
Oncology
News
Bexobrutideg Continues to Demonstrate Clinical Promise Following BTK Inhibitor Resistance in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
06/11/2026
Stephanie Holland
Updated results from a phase 1a/1b study show that bexobrutideg continues to demonstrate strong clinical promise in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Updated results from a phase 1a/1b study show that bexobrutideg continues to demonstrate strong clinical promise in chronic lymphocytic leukemia and small lymphocytic lymphoma.
Updated results from a phase...
06/11/2026
Oncology
News
Addition of Polatuzumab to R-ICE Falls Short in Second-Line Large B-Cell Lymphoma
06/11/2026
Stephanie Holland
Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory large B-cell lymphoma.
Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory large B-cell lymphoma.
Results from a phase 3 study...
06/11/2026
Oncology
News
Dual-Target CAR T Therapy OL-101 Shows Deep Responses in Heavily Pretreated Patients With Relapsed or Relapsed Multiple Myeloma
06/11/2026
Stephanie Holland
Results from an ongoing phase 1 study demonstrated that OL-101 shows strong clinical promise in heavily pretreated relapsed or refractory multiple myeloma.
Results from an ongoing phase 1 study demonstrated that OL-101 shows strong clinical promise in heavily pretreated relapsed or refractory multiple myeloma.
Results from an ongoing phase 1...
06/11/2026
Oncology

Podcasts

Elias Jabbour, MD
Podcasts
Olverembatinib Plus Blinatumomab Produces Deep Responses in Ph+ Acute Lymphoblastic Leukemia
06/05/2026
Elias Jabbour, MD
Elias Jabbour, MD, discusses results from a phase 1 study showing that olverembatinib plus blinatumomab induced high response rates and deep MRD-negative remissions in heavily pretreated patients with Philadelphia chromosome–positive acute...
Elias Jabbour, MD, discusses results from a phase 1 study showing that olverembatinib plus blinatumomab induced high response rates and deep MRD-negative remissions in heavily pretreated patients with Philadelphia chromosome–positive acute...
Elias Jabbour, MD, discusses...
06/05/2026
Oncology
Podcasts
Treatment of Recurrent Refractory Pediatric Low-Grade Glioma (pLGG)
01/02/2026
Cassie Kline, MD, MAS
Dr Cassie Klein presents a three-year update from the phase 2 FIREFLY-1 trial evaluating tovorafenib, a weekly oral type II RAF inhibitor, in recurrent or refractory pediatric low-grade glioma. She emphasizes the importance of incorporating...
Dr Cassie Klein presents a three-year update from the phase 2 FIREFLY-1 trial evaluating tovorafenib, a weekly oral type II RAF inhibitor, in recurrent or refractory pediatric low-grade glioma. She emphasizes the importance of incorporating...
Dr Cassie Klein presents a...
01/02/2026
Oncology
Podcasts
Case Files: Axatilimab Use in a Patient With Chronic Graft-Versus-Host-Disease 
09/16/2025
Benjamin Watkins, MD
A case-based discussion on using axatilimab, including toxicity experience. 
A case-based discussion on using axatilimab, including toxicity experience. 
A case-based discussion on using...
09/16/2025
Oncology
Podcasts
Navigating Second-Line Decisions: Real-World Management of Chronic Graft-Versus-Host Disease (GVHD)
09/16/2025
Shernan Holtan, MD
This podcast highlights results from a recent trial on the long-term effects of ruxolitinib in transplant patients with graft-versus-host disease. 
This podcast highlights results from a recent trial on the long-term effects of ruxolitinib in transplant patients with graft-versus-host disease. 
This podcast highlights results...
09/16/2025
Oncology
Podcasts
From Steroids to Second-Line Therapy—What Drives the Move? 
09/16/2025
Betty Hamilton, MD
An engaging discussion on what drives the move from steroids to a second-line or subsequent third-line therapy for chronic graft-versus-host disease? Are they really the definitions we see in trials, or are they different?
An engaging discussion on what drives the move from steroids to a second-line or subsequent third-line therapy for chronic graft-versus-host disease? Are they really the definitions we see in trials, or are they different?
An engaging discussion on what...
09/16/2025
Oncology
Podcasts
Beyond Symptoms: Navigating Chronic Graft-Versus-Host Disease Assessment 
09/16/2025
Yi-Bin Chen, MD
"Beyond Symptoms: Navigating Chronic Graft-Versus-Host Disease Assessment," which covers the symptomatic nature of cGVHD and provides quick tips for adequately assessing chronic graft-versus-host disease symptoms. 
"Beyond Symptoms: Navigating Chronic Graft-Versus-Host Disease Assessment," which covers the symptomatic nature of cGVHD and provides quick tips for adequately assessing chronic graft-versus-host disease symptoms. 
"Beyond Symptoms: Navigating...
09/16/2025
Oncology
Podcasts
Podcast: Selecting Second-Line Therapy for Relapsing/Remitting Pediatric Low-Grade Glioma (pLGG)
05/13/2025
Dr Eugene Hwang explores the evolving role of targeted therapies in recurrent pediatric low-grade glioma (pLGG)—balancing molecular precision, quality of life, and real-world treatment logistics in the quest for optimal care.
Dr Eugene Hwang explores the evolving role of targeted therapies in recurrent pediatric low-grade glioma (pLGG)—balancing molecular precision, quality of life, and real-world treatment logistics in the quest for optimal care.
Dr Eugene Hwang explores the...
05/13/2025
Oncology
Podcasts
Podcast: Targeted Therapies for Relapsing/Remitting Pediatric Low-Grade Glioma (R/R pLGG)
05/13/2025
Dr Eugene Hwang delves into the evolving landscape of MEK and BRAF inhibitors for pediatric low-grade glioma (pLGG), comparing efficacy, side effects, and next-gen strategies shaping frontline and salvage care.
Dr Eugene Hwang delves into the evolving landscape of MEK and BRAF inhibitors for pediatric low-grade glioma (pLGG), comparing efficacy, side effects, and next-gen strategies shaping frontline and salvage care.
Dr Eugene Hwang delves into the...
05/13/2025
Oncology
Dr Hwang
Podcasts
Podcast: Oncogenic Drivers of Pediatric Low-Grade Glioma (pLGG)
05/13/2025
Dr Eugene Hwang unpacks the molecular underpinnings of pediatric low-grade glioma (pLGG)—highlighting how MAPK pathway alterations are reshaping diagnosis, prognosis, and the promise of precision therapies.
Dr Eugene Hwang unpacks the molecular underpinnings of pediatric low-grade glioma (pLGG)—highlighting how MAPK pathway alterations are reshaping diagnosis, prognosis, and the promise of precision therapies.
Dr Eugene Hwang unpacks the...
05/13/2025
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
Sacituzumab Govitecan Plus Pembrolizumab in the TROPHY-U-01 Trial
03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares...
03/07/2024
Oncology

Interactive

Quiz
Quiz: Where is the GPRC5D Gene Expressed?
03/23/2023
True or False: The GPRC5D gene is typically expressed in hair follicles, but CD138-positive multiple myeloma cells have also been found to express GPRC5D.
True or False: The GPRC5D gene is typically expressed in hair follicles, but CD138-positive multiple myeloma cells have also been found to express GPRC5D.
True or False: The GPRC5D gene...
03/23/2023
Oncology
Quiz
Quiz: Principles Behind Choosing Optimal Therapeutic Agent Combinations for Patients With MM
03/20/2023
According to Dr Faith E. Davies, MD, which of the following is NOT a principle behind selecting an optimal combination of therapeutic agents for patients with multiple myeloma in the early relapse stage?
According to Dr Faith E. Davies, MD, which of the following is NOT a principle behind selecting an optimal combination of therapeutic agents for patients with multiple myeloma in the early relapse stage?
According to Dr Faith E. Davies,...
03/20/2023
Oncology
Quiz
Pivekimab Sunirine for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasms
06/09/2026
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA...
06/09/2026
Oncology
Quiz
Durvalumab Plus BCG for BCG-Naïve Patients With Non-Muscle Invasive Bladder Cancer
06/08/2026
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase...
06/08/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 4
05/21/2026
Lucia Masarova, MD
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 3
05/21/2026
Lucia Masarova, MD
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 2
05/21/2026
Lucia Masarova, MD
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 1
05/21/2026
Lucia Masarova, MD
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the...
05/21/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 5
05/21/2026
Michael R. Grunwald, MD
Learn more about the safety profile of interferon therapy in low-risk polycythemia vera.
Learn more about the safety profile of interferon therapy in low-risk polycythemia vera.
Learn more about the safety...
05/21/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 4
05/21/2026
Michael R. Grunwald, MD
Review clinical features that may support consideration of cytoreductive therapy in patients with low-risk polycythemia vera.
Review clinical features that may support consideration of cytoreductive therapy in patients with low-risk polycythemia vera.
Review clinical features that...
05/21/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 3
05/21/2026
Michael R. Grunwald, MD
Test your understanding of first-line cytoreductive therapy options for patients with high-risk polycythemia vera.
Test your understanding of first-line cytoreductive therapy options for patients with high-risk polycythemia vera.
Test your understanding of...
05/21/2026
Oncology
Current First-Line Treatments and Low-Risk Treatment Guidelines in Polycythemia Vera (PV): A Quiz Journey
PV Guidelines Question 2
05/20/2026
Learn when cytoreductive therapy should be considered for patients with low-risk polycythemia vera despite treatment with phlebotomy and aspirin.
Learn when cytoreductive therapy should be considered for patients with low-risk polycythemia vera despite treatment with phlebotomy and aspirin.
Learn when cytoreductive therapy...
05/20/2026
Oncology

GPRC5D Targeting Anticancer Drugs

GPRC5D is a promising immunotherapeutic target, particularly in patients with multiple myeloma. This table outlines therapies targeting GPRC5D in the pipeline.

Table icon
View Table
X

GPRC5D Targeting Anticancer Drugs in the Pipeline

Generic Drug Name

Potential Indications

Talquetamab1

A first-in-class investigational bispecific antibody targeting both GPRC5D and CD3 being evaluated for the treatment of patients with relapsed or refractory multiple myeloma.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use